Back to top
more

PerkinElmer, Inc. (PKI)

(Delayed Data from NYSE)

$96.59 USD

96.59
692,880

+1.71 (1.80%)

Updated May 3, 2019 04:03 PM ET

After-Market: $96.59 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Core Business Units Boost McKesson's (MCK) Q3 Earnings?

by Zacks Equity Research

McKesson (MCK) expects to gain from solid segmental performances in third-quarter fiscal 2019.

AmerisourceBergen (ABC) Q1 Earnings: What's in the Cards?

by Zacks Equity Research

AmerisourceBergen's (ABC) first-quarter fiscal 2019 results are likely to gain from its core Pharmaceutical Distribution business unit.

What's in Store for Edwards Lifesciences' (EW) Q4 Earnings?

by Zacks Equity Research

Edwards Lifesciences (EW) expected to see consistent performance by Surgical Structural Heart and Critical Care segments in Q4.

PerkinElmer (PKI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

PerkinElmer (PKI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's Setting the Tone for Hologic's (HOLX) Q1 Earnings?

by Zacks Equity Research

Strength in the Breast Health business, Panther system and international business is likely to boost Hologic's (HOLX) top line in Q1.

Will Core Renal Care Unit Fuel Baxter's (BAX) Q4 Earnings?

by Zacks Equity Research

Management at Baxter (BAX) expects Renal Care to see growth of 3-4% in 2018.

Can Diagnostic Revenues Fuel PerkinElmer's (PKI) Q4 Earnings?

by Zacks Equity Research

PerkinElmer's (PKI) fourth-quarter 2018 results are likely to benefit from the Diagnostics Segment's solid performance.

Can Overall Growth Fuel Align Technology's (ALGN) Q4 Earnings?

by Zacks Equity Research

Align Technology (ALGN) is likely to gain from strength in Invisalign space as well as Scanner and Service business in fourth-quarter 2018.

Will Core MedSurg Segment Aid Stryker's (SYK) Q4 Earnings?

by Zacks Equity Research

Stryker's (SYK) Q4 results are likely to be aided by its core MedSurg segment.

Will Instruments Fuel Intuitive Surgical (ISRG) Q4 Earnings?

by Zacks Equity Research

Intuitive Surgical's (ISRG) top line in the fourth quarter of 2018 is likely to benefit from solid grow that the Instruments and Accessories segment.

Varian Medical (VAR) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Strong overseas presence and product launches are likely to aid Varian Medical's (VAR) fiscal first-quarter results.

Here's Why You Should Invest in PerkinElmer (PKI) Stock Now

by Zacks Equity Research

Focus on emerging markets, improving margins and encouraging guidance provide PerkinElmer (PKI) a competitive edge in the MedTech space.

PerkinElmer (PKI) Up 5.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Stock Market News For Nov 27, 2018

by Zacks Equity Research

Markets closed sharply higher on Monday after posting steep losses last week.

PerkinElmer's Vanadis NIPT CE Mark Boosts Prenatal Prospects

by Zacks Equity Research

PerkinElmer's (PKI) Vanadis NIPT is a more cost effective and non-invasive screening system compared to traditional ones.

PerkinElmer (PKI) Misses on Q3 Earnings, Slashes EPS View

by Zacks Equity Research

Perkinelmer (PKI) gains from segmental performances in Q3; lowers 2018 EPS view.

PerkinElmer (PKI) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

PerkinElmer (PKI) delivered earnings and revenue surprises of -2.17% and -0.02%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Cardinal Health's (CAH) Q1 Earnings?

by Zacks Equity Research

Cardinal Health (CAH) likely to gain from solid Pharmaceutical revenues in fiscal Q1; medical-gloves sub-segment likely to be soft.

What's in Store for INSYS Therapeutics' (INSY) Q3 Earnings?

by Zacks Equity Research

Improvement in prescriptions growth rate of SUBSYS and SYNDROS to drive INSYS Therapeutics' (INSY) Q3 earnings.

What's in Store for Tandem Diabetes' (TNDM) Q3 Earnings?

by Zacks Equity Research

Strong domestic sales along with the recent launch of the t:slim X2 Insulin Pump in selected international markets likely to drive Tandem Diabetes' (TNDM) Q3 earnings.

Can BD Medical Drive Becton, Dickinson's (BDX) Q4 Earnings?

by Zacks Equity Research

Becton, Dickinson (BDX) likely to gain from strong segmental contributions in fiscal Q4.

Will Flagship Impella Drive Abiomed's (ABMD) Q2 Earnings?

by Zacks Equity Research

Abiomed (ABMD) likely to gain from flagship Impella in Q2; a competitive industry is a headwind.

Will Product Revenues Drive Masimo's (MASI) Q3 Earnings?

by Zacks Equity Research

Masimo's (MASI) Product revenues likely to drive Q3; guidance for 2018 raised.

What's in Store for Weight Watchers' (WTW) Q3 Earnings?

by Zacks Equity Research

Weight Watchers (WTW) likely to see soft segmental revenues in Q3; EPS guidance raised.

PerkinElmer (PKI) Q3 Earnings Preview: What's Shaping Up?

by Zacks Equity Research

PerkinElmer (PKI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.